Official development assistance

EMGA secures US$ 15M financing for Banco Improsa in Costa Rica

Retrieved on: 
Monday, April 22, 2024

EMGA’s Head of Investment Banking and Managing Director of EMGA, Sajeev Chakkalakal, stated: "In spite of a challenging global macroeconomic environment, we are pleased to once again facilitate Banco Improsa’s continued vision to supporting SMEs in Costa Rica and complete this financing solution."

Key Points: 
  • EMGA’s Head of Investment Banking and Managing Director of EMGA, Sajeev Chakkalakal, stated: "In spite of a challenging global macroeconomic environment, we are pleased to once again facilitate Banco Improsa’s continued vision to supporting SMEs in Costa Rica and complete this financing solution."
  • Commenting on the transaction, Felix Alpizar Lobo, General Manager of Banco Improsa, said: "This financing reaffirms our commitment to strengthening the SME segment in Costa Rica.
  • Banco Improsa is proud to share JICA's objective of contributing to the economic and social growth of developing countries."
  • Banco Improsa was one of the first private banks in Costa Rica to offer non-financial services to its clients and has a long-standing history of providing advice and support to SMEs.

EMGA secures US$ 50M debt finance for Kazakhstan’s MFO KMF

Retrieved on: 
Tuesday, April 9, 2024

KMF Chairman of the Board Shalkar Zhusupov: "This is the first time that KMF has entered into a partnership with JICA, whose goals and mission are close to our own.

Key Points: 
  • KMF Chairman of the Board Shalkar Zhusupov: "This is the first time that KMF has entered into a partnership with JICA, whose goals and mission are close to our own.
  • EMGA’s Head of Investment Banking and Managing Director Sajeev Chakkalakal said, “We are delighted to have arranged this new landmark debt facility for our long-standing client KMF.
  • MFO “KMF” disburses clients individual and group loans for the following types of activity: business, trade, crop farming and cattle-breeding, production and services and consumer lending.
  • Emerging Markets Global Advisory Limited (EMGA), with offices in London and New York, helps financial institutions and corporates seeking new debt or equity capital.

Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil

Retrieved on: 
Friday, July 1, 2022

In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.

Key Points: 
  • In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.
  • A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialisation of the vaccines in Brazil.
  • The collaboration also involves Emergex and IBMP conducting pre-clinical testing and clinical development of Chikungunya vaccine candidate.
  • Partnering with IBMP makes strategic sense for Emergex as it has the local contacts and expertise to successfully develop and commercialize our vaccines in Brazil.

EMGA advises on US$200M debt raise for BTG Pactual with JICA

Retrieved on: 
Thursday, March 10, 2022

A JICA spokesman said, Thanks to EMGAs support, we will partner Banco BTG Pactual S.A. addressing the funding gap for MSMEs in Brazil.

Key Points: 
  • A JICA spokesman said, Thanks to EMGAs support, we will partner Banco BTG Pactual S.A. addressing the funding gap for MSMEs in Brazil.
  • BTG Pactual is among the first to introduce digital platforms offering financial solutions to businesses throughout the whole nation.
  • JICA is an important partner of EMGA and its position as a pre-eminent development finance institution also offers another new strategic long term funding source for BTG.
  • Emerging Markets Global Advisory Limited (EMGA), with offices in London and New York, helps financial institutions and corporates seeking new debt or equity capital.

Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus

Retrieved on: 
Tuesday, February 22, 2022

The grant will cover the cost of generating a Chikungunya vaccine prototype.

Key Points: 
  • The grant will cover the cost of generating a Chikungunya vaccine prototype.
  • The project covers the identification of novel Chikungunya peptide epitopes (collectively constituting the ligandome), synthesis of a vaccine candidate and testing in in vitro efficacy models.
  • The funding, administered through UK Aid (Official Development Assistance) funding, was awarded following a Small Business Research Initiative (SBRI) competition funded by the DHSCs UK Vaccine Network (UKVN), delivered through Innovate UK.
  • Emergex will generate a fully synthetic Priming CD8+ T cell Adaptive Vaccine candidate by targeting regions of the Chikungunya virus that are common amongst all Togaviridae viruses.